Imperial College London
Portrait Picture

Dr Evangelos Triantafyllou

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Lecturer in Liver Immunology
 
 
 
//

Contact

 

e.triantafyllou Website

 
 
//

Location

 

10.N12ACommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Artru:2022:10.3389/fimmu.2022.867261,
author = {Artru, F and McPhail, MJW and Triantafyllou, E and Trovato, FM},
doi = {10.3389/fimmu.2022.867261},
journal = {Frontiers in Immunology},
pages = {1--21},
title = {Lipids in liver failure syndromes: a focus on eicosanoids, specialized pro-resolvinglipid mediators and lysophospholipids.},
url = {http://dx.doi.org/10.3389/fimmu.2022.867261},
volume = {13},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Lipids are organic compounds insoluble in water with a variety of metabolic and non-metabolic functions. They not only represent an efficient energy substrate but can also act as key inflammatory and anti-inflammatory molecules as part of a network of soluble mediators at the interface of metabolism and the immune system. The role of endogenous bioactive lipid mediators has been demonstrated in several inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, cancer). The liver is unique in providing balanced immunotolerance to the exposure of bacterial components from the gut transiting through the portal vein and the lymphatic system. This balance is abruptly deranged in liver failure syndromes such as acute liver failure and acute-on-chronic liver failure. In these syndromes, researchers have recently focused on bioactive lipid mediators by global metabonomic profiling and uncovered the pivotal role of these mediators in the immune dysfunction observed in liver failure syndromes explaining the high occurrence of sepsis and subsequent organ failure. Among endogenous bioactive lipids, the mechanistic actions of three classes (eicosanoids, pro-resolving lipid mediators and lysophospholipids) in the pathophysiological modulation of liver failure syndromes will be the topic of this narrative review. Furthermore, the therapeutic potential of lipid-immune pathways will be described.
AU  - Artru,F
AU  - McPhail,MJW
AU  - Triantafyllou,E
AU  - Trovato,FM
DO  - 10.3389/fimmu.2022.867261
EP  - 21
PY  - 2022///
SN  - 1664-3224
SP  - 1
TI  - Lipids in liver failure syndromes: a focus on eicosanoids, specialized pro-resolvinglipid mediators and lysophospholipids.
T2  - Frontiers in Immunology
UR  - http://dx.doi.org/10.3389/fimmu.2022.867261
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35432367
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2022.867261/full
UR  - http://hdl.handle.net/10044/1/96412
VL  - 13
ER  -
Download